[Comment] Moving Integrated Care Into the Community in Sub-Saharan Africa

Why It Matters

Integrating HIV and NCD services at the community level can preserve treatment gains, lower system costs, and improve patient adherence in resource‑constrained settings.

Key Takeaways

• Vertical HIV programs achieved rapid treatment scale‑up.
• HIV patients now face hypertension and diabetes prevalence.
• Community‑based integrated care matches facility outcomes.
• Trials show reduced travel costs and higher adherence.
• Funding gaps push for sustainable, blended service models.

Pulse Analysis

The legacy of vertical HIV programmes in sub‑Saharan Africa illustrates how disease‑specific funding can accelerate service delivery, yet it also created parallel infrastructures that struggle to address the growing burden of hypertension and diabetes among people living with HIV. As life expectancy rises, health ministries confront a dual epidemic that threatens to overwhelm clinic capacity and increase out‑of‑pocket expenses for patients traveling long distances.

Recent evidence from pragmatic cluster‑randomised trials—INTE‑AFRICA (2023) and INTE‑COMM (2026)—shows that deploying community health workers equipped with mobile decision‑support tools can deliver integrated HIV, diabetes, and hypertension care with outcomes comparable to tertiary facilities. These models cut transportation costs, improve medication adherence, and generate modest cost‑savings, especially when combined with same‑day antiretroviral initiation and point‑of‑care diagnostics.

For policymakers, the imperative is clear: scale community‑based integrated platforms while securing diversified financing beyond dwindling donor streams. Embedding NCD screening into existing HIV outreach, leveraging digital health platforms, and institutionalising performance‑based funding can create resilient, patient‑centred systems. Continued implementation research will be essential to refine task‑shifting protocols, assess long‑term sustainability, and guide regional guidelines that balance clinical efficacy with fiscal responsibility.